65,437 trials
Cervical Intraepithelial Neoplasia
Primary: Number of Subjects With Serious Adverse Events (SAEs) Related to Study Vaccine in Vacc-092 Group — 0 Participants
Rheumatoid Arthritis
Primary: Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission (≤ 3.3) at Week 48: Etanercept Monotherapy vs. Methotrexate Monotherapy — 28.7; 49.5…
Chronic Rhinosinusitis (Diagnosis) · Allergic Rhinosinusitis · Chronic Eosinophilic Rhinosinusitis
Primary: Change in Sino-Nasal Outcome Test Scores (SNOT-22) — 23.18; 17.7 score on a scale
Scars
Primary: Photographic Evaluation of Scar Clearance — 1.82 score on a scale
Astigmatism
Primary: Proportion of Participants Achieving a Contact Lens Corrected Distance logMAR VA of 0.04 or Better — 105; 92 Participants
Cancer
Primary: Objective Response Rate (ORR) — 7.9 Percent of Participants
Stroke · Cerebrovascular Disorders · Brain Diseases
Primary: Fugl-Meyer Arm Motor Scale — 59 units on a scale
Skin Wrinkling
Primary: Horizontal Diameter of the Fields of Anhidrotic Effect — 0.84; 1.24 centimeters
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1174; 1626; 1164 nanogram per milliliter (ng/mL)
HIV Infections
Primary: Number of Grade 2 or Greater AEs — 10; 2 Participants — p=0.07
Acute Kidney Failure
Primary: Urine Volume — 89; 329; 96; 392 ml
Breakthrough Bleeding
Primary: Endometrial Matrix Metalloproteinase Expression by Gel Densitometry — 1.33; 2.49 relative expression
Influenza
Primary: Number of Participants Aged 6 Months to < 9 Years Who Provided Serum Samples for Analysis: Groups 1 and 2 — 28; 30; 22; 28 Participants
Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index — 6.15; 14.85 events per hour — p=<0.001